Hepatitis Forums
Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on July 01, 2020, 12:37:49 pm
-
Among people whose direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV) is covered by Medicare, 6% discontinued therapy early between 2014 and 2016. This figure, while low, is still three times greater than the rate seen in clinical trials, and it was higher depending on individual characteristics of the people undergoing treatment for the virus, including which regimen they took and whether they had cirrhosis.
Thomas Riley III, MD, of Penn State, and colleagues conducted an analysis of 82,056 people on Medicare who started DAA treatment for HCV between January 2014 and September 2016. They defined treatment discontinuation as filling prescriptions for fewer weeks than expected for their prescribed DAA regimen. Their findings were published in the American Journal of Managed Care.
Read more...
https://www.hepmag.com/article/6-medicare-recipients-receiving-hep-c-treatment-discontinue-early